Short answer
STAAR SURGICAL CO (STAA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 26, 2025. Quarterly revenue was $95M (up 6.9% year over year) with net income of $9M.
Q3 2025 key financials · XBRL
- Revenue
- $95M
- +6.9% YoY · +113.7% QoQ
- Net income
- $9M
- −11.0% YoY · +152.8% QoQ
- Operating margin
- 19.5%
- Gross margin
- 82.2%
- EPS (diluted)
- $0.18
- −10.0% YoY · +152.9% QoQ
Source: XBRL data from the STAAR SURGICAL CO (STAA) Q3 2025 10-Q on SEC EDGAR. USD.
STAAR SURGICAL CO Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New transaction risk triggered by August 4, 2025 Alcon merger agreement, including employee, customer, and supplier disruption
- Most material update: Broadwood Group opposition, with 27.4% ownership and announced intent to vote against the merger
- Regulatory risk: Pending antitrust approvals in China and Japan, despite expiration of the HSR Act waiting period
- Legal risk: Merger litigation could delay or enjoin completion and increase management distraction
- Financial risk: Potential termination fee up to $43.4 million payable to Alcon if specified conditions occur
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other STAAR SURGICAL CO quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.